Meglumine antimoniate adverse reactions: Difference between revisions
Jump to navigation
Jump to search
Gerald Chi (talk | contribs) (Created page with "__NOTOC__ {{Meglumine antimoniate}} {{CMG}} <ref>{{Cite web | last = | first = | title = WHO Model Prescribing Information: Drugs Used in Parasitic Diseases - Second E...") |
Gerald Chi (talk | contribs) mNo edit summary |
||
| Line 3: | Line 3: | ||
{{CMG}} | {{CMG}} | ||
==Adverse effects== | |||
Electrocardiographic changes are dose-dependent and usually reversible; typically, T-wave inversion and prolongation of the Q-T interval precede serious dysrhythmias. | |||
Hepatic and renal function may be impaired. | |||
Headache, malaise, dyspnoea, skin rashes, facial oedema and abdominal pain are also occasionally associated with treatment.<ref>{{Cite web | last = | first = | title = WHO Model Prescribing Information: Drugs Used in Parasitic Diseases - Second Edition: Protozoa: Leishmaniasis: Meglumine antimoniate and sodium stibogluconate | url = http://apps.who.int/medicinedocs/en/d/Jh2922e/2.4.1.html#Jh2922e.2.4.1 | publisher = | date = | accessdate = }}</ref> | |||
<ref>{{Cite web | last = | first = | title = WHO Model Prescribing Information: Drugs Used in Parasitic Diseases - Second Edition: Protozoa: Leishmaniasis: Meglumine antimoniate and sodium stibogluconate | url = http://apps.who.int/medicinedocs/en/d/Jh2922e/2.4.1.html#Jh2922e.2.4.1 | publisher = | date = | accessdate = }}</ref> | |||
==References== | ==References== | ||
Latest revision as of 03:42, 7 January 2014
| Meglumine Antimoniate |
|---|
| GLUCANTIM® WHO Prescribing Information |
| Description |
| Indications and Usage |
| Contraindications |
| Warnings and Precautions |
| Adverse Reactions |
| Dosage and Administration |
| How Supplied |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Adverse effects
Electrocardiographic changes are dose-dependent and usually reversible; typically, T-wave inversion and prolongation of the Q-T interval precede serious dysrhythmias.
Hepatic and renal function may be impaired.
Headache, malaise, dyspnoea, skin rashes, facial oedema and abdominal pain are also occasionally associated with treatment.[1]
References
Adapted from the FDA Package Insert.